Table 1.

Demographic and clinical characteristics of the patients with PsA included in the study (n = 176).

CharacteristicsValues
Age, yrs, mean (SD)55.2 (11.8)
Sex
  Female87 (49.4)/male 89 (50.6)
Type of PsA
  Axial52 (29.5); axial only, 8 (4.5)
  Peripheral168 (95.5); peripheral only, 124 (70.5)
  Axial and peripheral44 (25)
Psoriasis everYes 168 (95.5); no 7 (4); unknown 1 (0.5)
Treatment
  NSAID10 (5.7)
  nbDMARD90 (51.1)
  bDMARD74 (41.7)
  Other (azathioprine, cyclosporine)2 (1.1)
Psoriasis duration, mos, mean (SD); median [IQR]204.1 (163); 146 [216]
PsA duration (mos), mean (SD); median [IQR]118.3 (109.8); 96 [97]
Hypertension51 (29)
DM27 (15.3)
DL49 (27.8)
DL treatment47 (26.7)
Personal CV events4 (2.3)
Familial CV events55 (31.3); unknown 7 (4)
BMI, kg/m2, mean (SD)29.4 (7.4)
BMI ≥ 25139 (79)
BMI ≥ 3069 (39.2)
Smokers41 (23.6)
Classic CV risk factors
  1 factor57 (32.3)
  2 factors43 (24.4)
  3 factors31 (17.6)
Uric acid, mg/dl, mean (SD); median [IQR]5.9 (1.5); 5 [2]
  < 7 mg/dl153 (86.9)
  ≥ 7 mg/dl18 (10.2)
Urate-lowering therapy7 (4)
Total cholesterol, mg/dl, mean (SD); median [IQR]191.4 (33.5); 191 [46]
  ≥ 200 mg/dl72 (41.1)
  < 200 mg/dl103 (58.9)
HDL cholesterol, mg/dl, mean (SD); median [IQR]55.3 (17.3); 54 [21]
LDL cholesterol, mg/dl, mean (SD); median [IQR]116.1 (31.5); 117 [44]
LDL ≥ 115, mg/dl95 (55.2)
LDL <115, mg/dl77 (44.8)
TG, mg/dl, mean (SD); median [IQR]120.6 (76.8); 98 [77]
  • Values are n (%) unless otherwise specified. IQR: interquartile range; PsA: psoriatic arthritis; NSAID: nonsteroidal antiinflammatory drugs; nbDMARD: nonbiologic disease-modifying antirheumatic drugs; bDMARD: biologic DMARD; DM: diabetes mellitus; DL: dyslipidemia; CV: cardiovascular; BMI: body mass index; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglycerides.